Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (61-70 of 297) with videos related to

Pageof 30
Sort By:
American Journal of Respiratory and Critical Care Medicine|July 18, 2025
Reply to Zeng: Redefining Accelerated PH in IPF: Uncovering Treatment Effects and Novel TriggersSteven D Nathan, Ho Cheol Kim, Christopher King, et al.
Expert Review of Respiratory Medicine|May 19, 2010
Potential of imatinib mesylate as a novel treatment for pulmonary fibrosisMantej Chhina, Oksana A Shlobin, Geraldine Grant, et al.
The European Respiratory Journal|May 7, 2026
ERJ Viewpoint: vascular targeted therapies for fibrotic lung disease - Start of a new era?Albina Tyker, Laura C Price, Steven D Nathan, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 12, 2003
Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipientsSteven D Nathan, Scott D Barnett, Julie Wohlrab, et al.
Journal of Clinical Medicine|March 27, 2025
Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH)Zein Kattih, Ho Cheol Kim, Shambhu Aryal, et al.
The European Respiratory Journal|February 8, 2020
FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further changeSteven D Nathan, Ming Yang, Elizabeth A Morgenthien, et al.
Future Cardiology|December 18, 2009
Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertensionMantej K Chhina, Weir Nargues, Geraldine M Grant, et al.
Contemporary Clinical Trials|November 27, 2020
Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosisLisa Lancaster, Ann Fieuw, Joyce Meulemans, et al.
Chest|July 8, 2015
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key QuestionsKeith C Meyer, Sonye K Danoff, Lisa H Lancaster, et al.
Thorax|March 25, 2022
Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosisAbhimanyu Chandel, Jean Pastre, Solène Valery, et al.
Pageof 30

Showing results (61-70 of 297) with videos related to

Sort By:
Pageof 30
American Journal of Respiratory and Critical Care Medicine|July 18, 2025
Reply to Zeng: Redefining Accelerated PH in IPF: Uncovering Treatment Effects and Novel TriggersSteven D Nathan, Ho Cheol Kim, Christopher King, et al.
Expert Review of Respiratory Medicine|May 19, 2010
Potential of imatinib mesylate as a novel treatment for pulmonary fibrosisMantej Chhina, Oksana A Shlobin, Geraldine Grant, et al.
The European Respiratory Journal|May 7, 2026
ERJ Viewpoint: vascular targeted therapies for fibrotic lung disease - Start of a new era?Albina Tyker, Laura C Price, Steven D Nathan, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 12, 2003
Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipientsSteven D Nathan, Scott D Barnett, Julie Wohlrab, et al.
Journal of Clinical Medicine|March 27, 2025
Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH)Zein Kattih, Ho Cheol Kim, Shambhu Aryal, et al.
The European Respiratory Journal|February 8, 2020
FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further changeSteven D Nathan, Ming Yang, Elizabeth A Morgenthien, et al.
Future Cardiology|December 18, 2009
Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertensionMantej K Chhina, Weir Nargues, Geraldine M Grant, et al.
Contemporary Clinical Trials|November 27, 2020
Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosisLisa Lancaster, Ann Fieuw, Joyce Meulemans, et al.
Chest|July 8, 2015
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key QuestionsKeith C Meyer, Sonye K Danoff, Lisa H Lancaster, et al.
Thorax|March 25, 2022
Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosisAbhimanyu Chandel, Jean Pastre, Solène Valery, et al.
Pageof 30